Plasma UCHL-1 as a Biomarker of Brain Injury in Hospitalized Foals With Neonatal Encephalopathy.

This research aimed to study whether the plasma biomarker ubiquitin carboxyl-terminal hydrolase L1 (UCHL-1) could serve as a reliable indicator of neonatal encephalopathy (NE) in young hospitalized foals. Although significant differences were found in plasma UCHL-1 concentrations among different diagnostic groups, the overall diagnostic and predictive value of this concentration was limited.

Introduction

• Neonatal encephalopathy (NE) is a disorder often seen in young foals, and differentiation from other disorders is crucial for equine practitioners.
• The study aimed to investigate if ubiquitin carboxyl-terminal hydrolase L1 (UCHL-1), a plasma biomarker, can reliably indicate the occurrence of NE and provide prognostic information.

Methodology

• The researchers conducted a prospective study involving 331 hospitalized foals of 4 days old or younger.
• The foals were categorized by the attending veterinarian into four clinical diagnosis groups: only NE, only sepsis, both NE and sepsis (NE+Sepsis), or neither NE nor sepsis (Other).
• Plasma UCHL-1 concentrations were measured using an ELISA method.

Results

• Medians of UCHL-1 concentrations were significantly higher for the NE and NE+Sepsis groups compared to the Other group.
• Foals that did not survive had significantly higher UCHL-1 concentrations on admission than those that survived.
• The receiver operator curve (ROC) analysis was performed to assess UCHL-1’s diagnostic and prognostic capabilities. This revealed it had a 73% sensitivity and 49% specificity for predicting NE, and 86% sensitivity and 43% specificity for predicting nonsurvival.

Conclusion

• Although there were significant differences in UCHL-1 concentrations between foals with NE or NE with sepsis and other diagnoses in this foal population, the diagnostic and prognostic value of UCHL-1 on admission was limited.